Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Future Oncology Année : 2021

Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis

Résumé

Aim: Comparison of the efficacy/safety/health-related quality of life of apalutamide, enzalutamide and darolutamide in Phase III clinical trials involving patients with nonmetastatic castration-resistant prostate cancer was performed. Materials and methods: Relevant studies were identified by searching PubMed as well as conference abstracts reporting updated overall survival. Three pivotal trials were identified, SPARTAN (apalutamide), PROSPER (enzalutamide) and ARAMIS (darolutamide), and form the basis of this analysis. Results: All three drugs significantly prolonged metastasis-free survival, prostate-specific antigen response and overall survival versus placebo, and were generally well tolerated. Conclusion: Drug selection will likely be influenced by tolerability/safety and other factors, such as the propensity for drug-drug interactions and the presence of comorbidities, that affect the risk-benefit balance in individual patients.
Fichier non déposé

Dates et versions

hal-03162307 , version 1 (08-03-2021)

Identifiants

Citer

Mathieu Roumiguie, Xavier Paoletti, Yann Neuzillet, Romain Mathieu, Sebastien Vincendeau, et al.. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis. Future Oncology, 2021, 17 (14), pp.1811-1823. ⟨10.2217/fon-2020-1104⟩. ⟨hal-03162307⟩
109 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More